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ارتباط تعدد األشكال اجلينية ألنزمي حتويل األجنيوتنسني واجللوتاثيون 
 س-ترانسفرييز مع مؤشر كتلة اجلسم بني اهلنود الشماليني
املصابني بارتفاع ضفط الدم
�سليحة ر�سوي، �سيد ت�سليم ر�سا، زيبا �سديقي، �سانيا عبا�ض، فرزانة مهدي
abstract: Objectives: This study aimed to examine the association of angiotensin-converting enzyme (ACE) and 
glutathione S-transferase (GST) gene polymorphisms with body mass index (BMI) in hypertensive North Indians. 
Methods: This case-control study was carried out between May 2013 and November 2014 at the Era’s Lucknow 
Medical College & Hospital, Lucknow, India, and included 378 subjects divided into three groups. One group 
constituted 253 hypertensive individuals (sustained diastolic blood pressure of >90 mmHg and systolic blood 
pressure of >140 mmHg) who were subcategorised according to normal (<25 kg/m2) or high (≥25 kg/m2) BMI. The 
third group consisted of 125 age-, gender- and ethnically-matched normotensive controls with a normal BMI. Gene 
polymorphisms were evaluated by polymerase chain reaction. The genotypic and allelic frequency distribution 
among both groups were analysed. Results: A significant difference was found between GST theta 1-null and 
GST mu 1-positive genotype frequencies among the hypertensive overweight/obese individuals and controls 
(P = 0.014 and 0.033, respectively). However, no difference was observed in the frequency of ACE polymorphisms. 
ACE insertion/insertion genotype (P = 0.006), insertion and deletion alleles (P = 0.007 each) and GST theta 1-null 
and GST theta 1-positive genotypes (P = 0.006 each) were found to differ significantly between hypertensive cases 
and controls, regardless of BMI. Conclusion: ACE and GST gene polymorphisms were not associated with BMI but 
were significantly associated with hypertension among the studied group of North Indians.
Keywords: Angiotensin Converting Enzyme; Glutathione Transferase; Genetic Polymorphisms; Hypertension; 
Body Mass Index; Obesity; India.
واجللوتاثيون   )ACE( الأجنيوتن�سني  حتويل  لأنزمي  اجليني  الأ�سكال  تعدد  ارتباط  درا�سة  اإىل  الدرا�سة  هذه  هدفت  الهدف:  امللخ�ص: 
�ض-تران�سفرييز )GST( مع موؤ�رس كتلة اجل�سم بني الهنود ال�سماليني ذوي مر�ض �سفط الدم املرتفع. الطريقة: اأجريت هذه الدرا�سة املقارنة 
بني احلالت وجمموعة التحكم بني مايو 2013 ونوفمرب 2014 يف كلية ايرا�ض لكناو الطبية وم�ست�سفى، لكناو، ولية اوتار برادي�ض، الهند، 
و�سملت 378 �سخ�ض مت تق�سيمهم اإىل ثالث جمموعات. ت�سكل املجموعة الأوىل 253 من الأفراد امل�سابني بارتفاع �سغط الدم )�سغط الدم 
النب�ساطي امل�ستمر 90> مم زئبق و�سغط الدم النقبا�سي 140> مم زئبق( الذين مت تق�سيمهم بعد ذلك ح�سب كتلة اجل�سم اىل )25< كجم/
م2( و)25≤ كجم/م2( وتاألفت املجموعة الثالثة من 125 متماثلي العمر واجلن�ض والعرق و �سغط الدم و موؤ�رس كتلة ج�سم طبيعيني. مت تقييم 
اجلينات متعددة الأ�سكال عن طريق تفاعل البلمرة املت�سل�سل. وقد مت حتليل توزيع الرتدد الوراثي واأليلية بني املجموعتني. النتائج: وجد 
فرق كبري بني وترية النمط اجليني ل GST ثيتا 1 امل�سفر و GST ميوالإيجابي بني الأفراد امل�سابني بارتفاع �سغط الدم و يعانون من 
 .ACE على التوايل(. ومع ذلك، مل يالحظ اأي اختالف يف تعدد اأ�سكال ،P = 0.033 و P = 0.014( زيادة الوزن/ال�سمنة وال�سوابط الأ�سحاء
 GST ثيتا 1-ا امل�سفر و GST لكل منهما( و P = 0.007( واإدراج وحذف الأليالت ،)P = 0.006( ACE بالن�سبة لالإدراج/احلذف اجليني ل
ثيتا 1 الإيجابي )P = 0.006 لكل منهما( وجد اأن هناك اختالف اح�سائي بني حالت ارتفاع �سغط الدم واملجموعة ال�سابطة بغ�ض النظر 
عن موؤ�رس كتلة اجل�سم. اخلال�صة: مل يرتبط تعدد الأ�سكال اجليني ل ACE و GST مع موؤ�رس كتلة اجل�سم لكن ارتبط اإح�سائيا مع ارتفاع 
�سغط الدم يف جمموعة البحث من الهنود ال�سماليني.
اجل�سم؛  كتلة  موؤ�رس  الدم؛  ارتفاع �سغط  اجلينية؛  الأ�سكال  تعدد  تران�سفريز؛  اجللوتاثيون  لالأجنيوتن�سني؛  املحول  الإنزمي  الكلمات:  مفتاح 
ال�سمنة؛ الهند.
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Advances in Knowledge 
- To the best of the authors’ knowledge, this is the first study to investigate the effect of single nucleotide polymorphisms in angiotensin-
converting enzyme (ACE) and glutathione S-transferase (GST) genes on body mass index (BMI) in hypertensive North Indians.
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Hypertension and obesity are emer-ging global health concerns.1 Many epidemiological studies have shown an 
association between these medical conditions.2,3 
Hypertension predisposes individuals to future weight 
gain as compared to their normotensive counterparts, 
which means that even hypertensive individuals 
at a normal weight are at significantly higher risk 
of becoming obese.4 The body mass index (BMI) 
is used to classify individuals according to various 
weight categories. A high BMI is associated with 
an increased burden of diabetes, hypertension and 
cardiovascular diseases.1 Aside from environmental 
and lifestyle factors, BMI is also influenced by genetic 
factors. Research has confirmed the involvement of 
different genetic polymorphisms in the metabolism 
and appetite of predisposed individuals, thus causing 
them to become overweight or obese.1 More than 41 
loci on the human genome have been linked with the 
development of obesity.1
The angiotensin-converting enzyme (ACE) is part 
of the renin-angiotensin system, which is responsible 
for regulating blood pressure and the balance of fluids 
and salts inside the body. Engeli et al. suggested that 
components of the renin-angiotensin system might be 
involved in the development of obesity and associated 
hypertension.5 The insertion/deletion polymorphism 
occurs in intron 16 of the ACE gene due to the pre-
sence or absence of a 278 base pairs (bp) Arthrobacter 
luteus repetitive sequence.6 This polymorphism has 
been found to drastically affect ACE activity where 
the deletion/deletion genotype increases ACE activity 
while the insertion/insertion genotype decreases 
activity.7 A study conducted in Pakistan showed the 
association of the ACE gene polymorphism with 
obesity, suggesting a role for the deletion allele in 
adipogenesis and adipocyte metabolism.8
Hirata et al. confirmed the role of oxidative 
stress in linking obesity with hypertension.9 Systemic 
oxidative stress levels increase obesity, which may lead 
to the development of obesity-related hypertension. 
Glutathione S-transferase (GST) plays a major role 
in combating reactive oxygen species, thus protecting 
the body against its harmful effects.10 Evidence also 
indicates the involvement of oxidative stress with the 
pathogenesis of hypertension.9 Among humans, the 
gene coding for GST mu 1 (GSTM1) and GST theta 1 
(GSTT1) are located on chromosomes 1p13.3 and 
22, respectively. Previous studies have demonstrated 
that GST polymorphisms were not associated with 
BMI in diabetic North Indians or with weight gain in 
schizophrenic Koreans.11,12 Since there is a close link 
between hypertension and obesity, this study sought 
to investigate the association of ACE and GST gene 
polymorphisms with BMI among a selected group of 
hypertensive North Indians.
Methods
This case-control study was carried out between 
May 2013 and November 2014 at the Era’s Lucknow 
Medical College & Hospital, Lucknow, India. A 
total of 253 subjects with either a recent diagnosis 
or history of hypertension were recruited from the 
Department of Medicine at Era’s Lucknow Medical 
College & Hospital. These patients mostly resided 
in Lucknow and adjoining areas, including Hardoi 
and Barabanki. A diagnosis of hypertension was 
based on sustained diastolic blood pressure of >90 
mmHg and systolic blood pressure of >140 mmHg. 
Hypertensive patients were subsequently subcate-
gorised according to BMI into normal weight 
(BMI <25 kg/m2) or overweight/obese (≥25 kg/m2) 
groups. As a control group, 125 age-, gender- and 
ethnically-matched normotensive individuals of 
normal weight (BMI <25 kg/m2) were recruited 
for inclusion in the study. Patients who visited the 
outpatient clinics for minor illnesses and with no 
history of major clinical diseases were recruited as 
controls. Subjects in either group with a history of 
smoking or evidence of cancer, organ dysfunction 
or metabolic disease were excluded. The sample size 
calculations were based on the proportion of ACE 
genotypes among the cases and controls using the 
following formula:
Based on a 95% level of significance and 80% 
expected power (20% type 2 error), the minimum 
sample size was 103 in each group. Subject to the 
N = (Zα + Zβ)2/{ln (1-e)}*[{(1-p1)/p1} + (1-p2)/p2}]
- While ACE and GST gene polymorphisms were not found to be associated with BMI among this study population, they were significantly 
associated with hypertension.
Application to Patient Care
- The results of this study could be helpful in understanding the impact of genetic polymorphisms on BMI and on an individual’s 
predisposition to hypertension.
- Additionally, these findings could contribute in the identification of novel factors leading to the development of a high BMI; this would 
assist in the prevention and cure of various related metabolic diseases.
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availability of cases, this was then increased so that the 
power would increase correspondingly.
Clinical data were collected from each subject, 
including gender, age, alcohol consumption, waist-to-
hip ratio (WHR), weight, height and family history. 
Quetelet’s equation (weight in kg/height in m2) was 
used to calculate the BMI of each participant. WHR 
was calculated by dividing the waist circumference 
at the narrowest point above the hip by the hip 
circumference at its greatest gluteal protuberance. 
Serum triglycerides were measured using the 
glycerol phosphate oxidase-peroxidase-amidopyrine 
method while serum cholesterol was measured by 
the cholesterol oxidase-peroxidase method. High-
density lipoprotein cholesterol was measured by the 
immunoinhibition method using the Erba XL-300 
fully automated chemistry analyser (Erba Diagnostics 
Mannheim GmbH, Mannheim, Germany). Very low-
density lipoprotein levels were estimated by dividing 
measured triglycerides by 5 mg/dL units. Low-density 
lipoprotein cholesterol levels were estimated using the 
Friedewald formula.13 
The DNA extraction was performed using 3 mL 
of venous blood collected from all participants in 
0.5 M ethylenediaminetetraacetic acid tubes. A stan- 
dard phenol-chloroform extraction method was used 
to isolate genomic DNA from the blood samples.14 
The DNA concentration was determined by a 
spectrophotometer and samples were stored at -20 °C. 
ACE insertion/deletion polymorphisms (rs464994) 
were analysed by genomic DNA amplification using 
polymerase chain reaction (PCR) technology.15 PCR 
amplification was conducted in a total volume of 
20 µL using: 10 pmol each of forward primer 5’-CT-
GGAGACCACTCCCATCCTTTCT-3’ and reverse 
primer 5’-GATGTGGCCATCTTCGTCAGAT-3’; 200 
ng of genomic DNA; 3 mM of magnesium chloride; 
50 mM of potassium chloride; 10 mM of trisamino-
methane hydrochloride at a pH of 8.4; 0.5 mM 
each of deoxyribonucleotide triphosphate; and 2 
U of Thermus aquaticus (Taq) polymerase (Bioline 
Reagents Ltd., London, UK). The PCR amplification 
was performed using an initial denaturation at 94 °C for 
five minutes, followed by 35 cycles of denaturation at 
94 °C for 45 seconds, annealing at 60 °C for one minute 
and 15 seconds, extension at 72 °C for two minutes 
and 30 seconds and final extension at 72 °C for five 
minutes. The amplified products were separated on a 
2.0% agarose gel stained with 0.5 ug/mL of ethidium 
bromide and visualised using a bioimaging and 
gel documentation system (UVP LLC, Upland, 
California, USA). 
The GSTM1 and GSTT1 genetic polymorphisms 
were analysed by genomic DNA amplification 
using the multiplex-PCR technique (MJ Mini™ 
Thermal Cycler, Bio Rad Laboratories Inc., Hercules, 
California, USA).15 Primers for GSTM1 were 
5’-AACTCCCTGAAAAGCTAAAGC-3’ and 5’-GTT- 
GGGCTCAAATATACGGTGG-3’, while primers for 
GSTT1 were 5’-TTCCTTACTGGTCCTCACATCT 
C-3’ and 5’-TCACCGGACATGGCCAGCA-3’. To 
avoid false-negative readings, β-globin was used 
as an internal control. Primers for β-globin were 
5’-CAACTTCATCCACGTTCACC-3’ and 5’-GAA 
GAGCCAAGGACAGGTAC-3’. PCR amplification 
was conducted in a total volume of 25 μL using: 
10 pmol of each primer; 100 ng of genomic DNA; 
2.5 mmol/L of magnesium chloride; 0.2 mmol/L 
each of deoxyribonucleotide triphosphate; and 1 U 
of Taq polymerase (Bioline Reagents Ltd). The 
PCR amplification was performed using an initial 
denaturation at 94 °C for five minutes, followed by 30 
cycles at 94 °C for one minute, 64 °C for one minute, 
72 °C for one minute and a final extension of 72 °C for 
seven minutes. Amplified products were separated on 
a 1.5% agarose gel stained with 0.5 μg/mL of ethidium 
bromide and visualised using a bioimaging and gel 
documentation system (UVP LLC). Direct sequencing 
was carried out for approximately 10% of all samples 
for both polymorphisms studied and genotyping for 
20% of the samples was further duplicated. The results 
were verified by two individual laboratory technicians 
to confirm genotyping results. 
Statistical analysis was performed using the Statis-
tical Package for the Social Sciences (SPSS), Version 
12 (IBM Corp., Chicago, Illinois, USA). Variables 
were tested for normality using the Kolmogorov- 
Smirnov test. Variables with a normal distribution 
were expressed as means ± standard deviation 
while variables with a non-normal distribution were 
expressed as medians and interquartile ranges and 
were log transformed before statistical analysis. A 
Chi-squared test was used to compare genotyping 
data between cases and controls. A P value of ≤0.050 
was considered significant. The odds ratio (OR) and 
95% confidence interval (CI) was calculated to test 
the relative risk for association. Other variables were 
compared using the Student’s t-test for normally-
distributed variables. 
Ethical approval for this study was granted by the 
Institutional Ethical Committee of the Department of 
Medicine at Era’s Lucknow Medical College & Hospital 
(#ELMC/E-1/3942). Written informed consent was 
obtained from each subject prior to data collection.
Results
A total of 378 patients were included in this study, 
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ranging in age from 26‒60 years old. There were 103 
subjects in the hypertensive normal weight group, 150 
subjects in the hypertensive overweight/obese group 
and 125 subjects in the control group. Obesity-related 
parameters were higher in the hypertensive groups 
compared to the control group [Table 1]. For ACE 
polymorphisms, a single 490 bp band represented an 
insertion/insertion genotype, two bands of 490 bp and 
190 bp represented an insertion/deletion genotype, 
whereas the deletion/deletion genotype was confirmed 
by a single band of 190 bp [Figure 1]. For GST genetic 
polymorphisms, the band sizes observed were 215 bp, 
480 bp and 268 bp for GSTM1, GSTT1 and β-globin, 
respectively [Figure 2]. Negligible discrepancy in 
genotyping was observed.
The genotype frequencies of ACE insertion/
deletion, deletion/deletion and insertion/insertion 
genotypes among the hypertensive overweight/obese 
group and the hypertensive normal weight group 
were 53.34%, 19.33% and 27.33% and 54.37%, 16.50% 
and 29.13%, respectively (OR = 0.96, 1.22 and 0.91; 
95% CI = 0.56–1.66, 0.59–2.49 and 0.50–1.67; P = 
 
Figure 1: Agarose gel image showing polymerase chain 
reaction products for an angiotensin-converting enzyme 
polymorphism. Lanes 1, 2 and 8 show the insertion/
insertion genotype at 490 base pairs (bp), lanes 6 and 7 
show the insertion/deletion genotype at 490 bp and lanes 
3 and 5 show the deletion/deletion genotype in a single 
band of 190 bp. Lane 4 is a 100 bp ladder.
 
Figure 2: Agarose gel image showing polymerase chain 
reaction products of glutathione S-transferase (GST) 
polymorphisms. The presence or absence of GST mu 
1 (GSTM1) and GST theta 1 (GSTT1) was detected by 
480 base pairs (bp) and 210 bp bands, respectively. 
β-globin was considered an internal control at 260 bp. 
Lanes 1 and 7 show GSTM1- and GSTT1-null genotypes, 
respectively, and lanes 2–5 show GSTM1 and GSTT1 
wild-type genotypes. Lane 4 is a 100 bp ladder. 
Table 1: Characteristics of overweight/obese* hypertensive subjects and hypertensive subjects of a normal weight† in 
comparison to an age-, gender- and ethnically-matched control group† in North India (N = 378)






 (n = 103)
Control group 
(n = 125)
Male-to-female ratio 83:67 72:53 0.706 58:45 72:53 0.845
Age in years 43.42 ± 13.29 40.03 ± 10.28 0.017 42.02 ± 16.65 40.03 ± 10.28 0.290
BMI in kg/m2 28.87 ± 3.78 21.92 ± 2.60 <0.001 21.68 ± 1.93 21.92 ± 2.60 0.424
SBP in mm Hg 147.63 ± 21.16 110.00 ± 10.61 <0.001 146.96 ± 17.87 110.00 ± 10.61 <0.001
DBP in mm Hg 97.85 ± 4.02 75.00 ± 9.20 <0.001 93.50 ± 5.67 75.00 ± 9.20 <0.001
SC in mg/dL 194.92 ± 43.27 166.73 ± 24.17 <0.001 181.11 ± 56.88 166.73 ± 24.17 0.017
Median TG in mmol/L-1 
(IQR)
2.12 (1.50–2.62) 1.32 (0.95–2.10) <0.001 1.94 (0.96–1.98) 1.32 (0.95–2.10) <0.001
HDL in mg/dL 41.24 ± 8.53 55.23 ± 9.59 <0.001 45.77 ± 8.79 55.23 ± 9.59 <0.001
VLDL in mg/dL 34.41 ± 20.55 30.83 ± 11.64 0.070 33.53 ± 16.7 30.83 ± 11.64 0.166
LDL in mg/dL 102.82 ± 47.44 87.80 ± 19.83 <0.001 103.78 ± 31.93 87.80 ± 19.83 <0.001
WHR 0.93 ± 0.02 0.86 ± 0.08 <0.001 0.86 ± 0.06 0.86 ± 0.08 0.667
SD = standard deviation; HH = hypertensive overweight/obese group; HN =hypertensive normal weight group; BMI = body mass index; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; SC = serum cholesterol; TG = triglycerides; IQR = interquartile range; HDL = high-density 
lipoproteins; VLDL = very low-density lipoproteins; LDL = low-density lipoproteins; WHR = waist-to-hip ratio.
*BMI ≥25 kg/m2. †BMI <25 kg/m2. ‡Calculated using the Student’s t-test. A P value of ≤0.050 was considered significant. 
Saliha Rizvi, Syed T. Raza, Zeba Siddiqi, Shania Abbas and Farzana Mahdi
Clinical and Basic Research | e481
0.889, 0.586 and 0.757). In the control group, the same 
ACE genotype frequencies were 59.20%, 27.20% and 
13.60%, respectively (OR = 0.86, 0.68 and 2.37; 95% 
CI = 0.49–1.48, 0.35–1.31 and 1.16–4.83; P = 0.575, 
0.245 and 0.015). Frequencies of insertion and deletion 
alleles were 54.00% and 46.00% for the hypertensive 
overweight/obese group compared to 56.31% and 
43.69% for the hypertensive normal weight group (OR 
= 0.91 and 1.10; 95% CI = 0.61–1.34 and 0.75–1.63; 
P = 0.620 each) and 43.20% and 56.80% for the 
control subjects, respectively (OR = 1.60 and 0.63; 95% 
CI = 1.08–2.36 and 0.42–0.92; P = 0.018 each) 
[Tables 2 and 3].
The GSTM1-null genotype frequency was 33.33% 
for the hypertensive overweight/obese group, while it 
was 36.89% and 45.60% for the hypertensive normal 
weight and control groups, respectively (OR = 0.84 
and 0.61; 95% CI = 0.47–1.50 and 0.35–1.07; P = 0.559 
Table 2: Frequencies of angiotensin-converting enzyme and glutathione S-transferase genetic polymorphisms among 
overweight/obese* hypertensive subjects and hypertensive subjects of a normal weight† in North India (N = 253)





I/D 56 (54.37) 80 (53.34) 0.96 0.56–1.66 0.02 0.889 0.610
D/D 17 (16.50) 29 (19.33) 1.22 0.59–2.49 0.30 0.586 0.813
I/I 30 (29.13) 41 (27.33) 0.91 0.50–1.67 0.10 0.757 0.622
I 116 (56.31) 162 (54.00) 0.91 0.61–1.34 0.25 0.620 0.735
D 90 (43.69) 138 (46.00) 1.10 0.75–1.63 0.25 0.620 0.735
GSTT1/GSTM1-positive 49 (47.57) 80 (53.34) 1.26 0.73–2.18 0.70 0.403 0.900
GSTT1-null 16 (15.53) 20 (13.33) 0.86 0.39–1.86 0.16 0.693 0.654
GSTM1-positive 65 (63.12) 100 (66.67) 1.19 0.67–2.11 0.34 0.559 0.822
GSTT1 -positive 87 (84.47) 130 (86.67) 1.17 0.54–2.54 0.16 0.693 0.753
GSTM1-null 38 (36.89) 50 (33.33) 0.84 0.47–1.50 0.34 0.559 0.763
OR = odds ratio; CI = confidence interval; HN = hypertensive normal weight group; HH = hypertensive overweight/obese group; ACE = angiotensin-
converting enzyme; I = insertion; D = deletion; GST = glutathione S-transferase; GSTT1 = GST theta 1; GSTM1 = GST mu 1. 





















Table 3: Frequencies of angiotensin-converting enzyme and glutathione S-transferase genetic polymorphisms among 
overweight/obese* hypertensive subjects in comparison to an age-, gender- and ethnically-matched control group† in 
North India (N = 275)





I/D 74 (59.20) 80 (53.34) 0.86 0.49–1.48 0.31 0.575 0.812
D/D 34 (27.20) 29 (19.33) 0.68 0.35–1.31 1.35 0.245 0.922
I/I 17 (13.60) 41 (27.33) 2.37 1.16–4.83 5.86 0.015 0.908
I 108 (43.20) 162 (54.00) 1.60 1.08–2.36 5.60 0.018 0.882
D 142 (56.80) 138 (46.00) 0.63 0.42–0.92 5.60 0.018 0.882
GSTT1/GSTM1-positive 63 (50.40) 80 (53.34) 1.22 0.70–2.10 0.49 0.486 0.811
GSTT1-null 5 (4.00) 20 (13.33) 3.89 1.23–12.27 6.09 0.014 0.900
GSTM1-positive 68 (54.40) 100 (66.67) 1.84 1.05–3.24 4.54 0.033 0.900
GSTT1 -positive 120 (96.00) 130 (86.67) 0.46 0.18–1.20 2.60 0.107 0.885
GSTM1-null 57 (45.60) 50 (33.33) 0.61 0.35–1.07 2.94 0.086 0.879
OR = odds ratio; CI = confidence interval; HH = hypertensive overweight/obese group; ACE = angiotensin-converting enzyme; I = insertion; 
D = deletion; GST = glutathione S-transferase; GSTT1 = GST theta 1; GSTM1 = GST mu 1. 





















Association of Angiotensin-Converting Enzyme and Glutathione S-Transferase Gene Polymorphisms with Body Mass Index among 
Hypertensive North Indians
e482 | SQU Medical Journal, November 2015, Volume 15, Issue 4
and 0.086). The frequency of the GSTT1-null genotype 
was 13.33% among the hypertensive overweight/obese 
group as compared to 15.53% and 4.00% among the 
hypertensive normal weight and control groups, 
respectively (OR = 0.86 and 3.89; 95% CI = 0.39–1.86 
and 1.23–12.27; P = 0.693 and 0.014). The frequencies 
of GSTM1- and GSTT1-positive genotypes were 
66.67% and 86.67% in the hypertensive overweight/
obese group, while they were 63.12% and 84.47% for 
the hypertensive normal weight group (OR = 1.19 and 
1.17; 95% CI = 0.67–2.11 and 0.54–2.54; P = 0.559 
and 0.693) and 54.40% and 96.00% in the control group, 
respectively (OR = 1.84 and 0.46; 95% CI = 1.05–3.24 
and 0.18–1.20; P = 0.033 and 0.107). The frequency 
of the GSTT1-/GSTM1-positive genotype was 
53.34% in the hypertensive overweight/obese group, 
47.57% for the hypertensive normal weight group and 
50.40% in the control group (OR = 1.26 and 1.22; 95% 
CI = 0.73–2.18 and 0.70–2.10; P = 0.403 and 0.486) 
[Tables 2 and 3].
The ACE insertion/insertion genotype frequency 
among the combined overweight/obese and normal 
weight hypertensive groups was 28.07% compared 
to 13.60% in the control group (OR = 2.41; 95% CI = 
1.27–4.57; P = 0.006). The deletion/deletion genotype 
frequency was 17.18% among hypertensives compared 
to 27.20% among healthy controls (OR = 0.59; 95% CI 
= 0.34–1.04; P = 0.068). Among the hypertensives, 
frequencies of the insertion and deletion alleles were 
55.14% and 44.86%, respectively, compared with 
43.20% and 56.80% in the control group, respectively 
(OR = 1.59 and 0.63; 95% CI = 1.13–2.24 and 0.45–
0.88; P = 0.007 each). The frequencies of the GSTT1- 
and GSTM1-null genotypes in the hypertensive groups 
were 14.69% and 34.78%, respectively (OR = 4.09 and 
0.63; 95% CI = 1.40–11.96 and 0.39–1.03; P = 0.006 
and 0.062). A significant difference was found between 
the GSTT1-null (14.69% versus 4.00%) and -positive 
(85.37% versus 96.00%; OR = 0.24; 95% CI = 0.08–0.71; 
P = 0.006) genotypes among the hypertensive groups 
in comparison to the control group. However, there 
was a non-significant difference between frequencies 
of GSTM1-positive genotypes (65.22% versus 54.40%; 
OR = 1.59; 95% CI = 0.97–2.58; P = 0.062) [Table 4].
Discussion
Hypertension and obesity may have a mutual or 
reciprocal relationship, where the presence of one 
potentially leads to the other.4 Studies have shown 
that the prevalence of hypertension is directly related 
to a higher BMI.2,3 In the current study, lipid profile 
variables (including serum cholesterol, triglycerides, 
low- and very low-density lipoproteins and WHR) 
were higher among the hypertensive individuals than 
the healthy controls, regardless of BMI category. 
Various studies have demonstrated increased plasma 
renin activity and plasma angiotensinogen, angiotensin 
II and aldosterone levels in obese individuals.16–18 
Cooper et al. pointed out that the ACE insertion/
deletion polymorphism was linked to changes in ACE 
levels, but was inconsistently associated with BMI.19
Table 4: Frequencies of angiotensin-converting enzyme and glutathione S-transferase genetic polymorphisms among 
hypertensive subjects in comparison to an age-, gender- and ethnically-matched control group in North India (N = 378)






I/D 137 (54.15) 74 (59.20) 0.81 0.50–1.32 0.71 0.398 0.913
D/D 45 (17.18) 34 (27.20) 0.59 0.34–1.04 3.33 0.068 0.935
I/I 71 (28.07) 17 (13.60) 2.42 1.27–4.57 7.50 0.006 0.969
I 279 (55.14) 108 (43.20) 1.59 1.13–2.24 7.25 0.007 0.940
D 227 (44.86) 142 (56.80) 0.63 0.45–0.88 7.25 0.007 0.940
GSTT1/GSTM1-positive 128 (50.59) 63 (50.40) 1.02 0.63–1.64 0.01 0.936 N/A
GSTT1-null 37 (14.69) 5 (4.00) 4.09 1.40–11.96 7.61 0.006 0.969
GSTM1-positive 165 (65.22) 68 (54.40) 1.59 0.97–2.58 3.47 0.062 0.880
GSTT1 -positive 216 (85.37) 120 (96.00) 0.24 0.08–0.71 7.61 0.006 0.984
GSTM1-null 88 (34.78) 57 (45.60) 0.63 0.39–1.03 3.47 0.062 0.910
OR = odds ratio; CI = confidence interval; ACE = angiotensin-converting enzyme; I = insertion; D = deletion; GST = glutathione S-transferase; 
GSTT1 = GST theta 1; GSTM1 = GST mu 1. 
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A study of a Saudi population noted a higher 
frequency of the mutant deletion allele in hypertensive 
cases with a BMI of ≥30 kg/m2 in comparison to 
controls, although the difference was not significant.20 
However, this result was reversed in the current 
study, as the frequency of the deletion allele among 
the hypertensive overweight/obese group was 
significantly lower than the control group. A similar 
study performed on Korean women also confirmed 
this finding (P = 0.063).21 Similarly, Passaro et al. 
showed that subjects with different polymorphisms 
in the ACE gene did not show significant variability 
in BMI.22 The frequency of the ACE deletion/deletion 
genotype among hypertensive overweight/obese 
individuals in the current study (19.33%) was similar to 
that found among an overweight Pakistani population 
(18.00%).8 The frequency of the ACE insertion/
insertion genotype in the hypertensive overweight/
obese group of the current study (27.33%) was similar 
to that found among obese Pakistani individuals 
(26.00%); however, it was lower than the frequency 
found among overweight Pakistanis (32.00%).8 
Eisenmann et al. reported that children with the 
ACE deletion/deletion genotype had a higher BMI 
compared to insertion/insertion carriers;23 this is 
consistent with the results obtained in the current 
study when comparing the hypertensive groups 
according to BMI, although this was not found to be 
significant. These results are contradictory to another 
report which demonstrated that the mutant deletion 
allele was associated with a low BMI.24 On further 
comparison of the hypertensive overweight/obese 
and control groups in the current study, a significant 
difference was found between the frequency of the 
insertion/insertion genotype and between the allele 
frequencies of insertion and deletion alleles. While no 
significant association was found between the ACE 
insertion/deletion polymorphism and BMI in the 
hypertensives, a significant association was observed 
with hypertension. This suggests that the ACE 
insertion/deletion polymorphism affects hypertension 
as opposed to BMI, with carriers of the insertion/
insertion genotype being more prone to hypertension. 
The insertion/insertion genotype frequency in the 
combined North Indian hypertensive population of 
the current study (28.07%) was similar to that found 
in hypertensive Pakistanis (29.30%) and another North 
Indian population (28.62%).15,25 There was a significant 
association between the ACE insertion/insertion 
genotype and hypertension; this contrasts with the 
results of a study conducted among South Indians, 
although it is similar to that of the other study on 
North Indians.15,26 
The current study found an association between 
the ACE deletion/deletion genotype and hypertension, 
although this was not significant. The frequency of this 
genotype among hypertensives in the current study 
(17.18%) was higher than that found for Malaysian 
and Bangladeshi individuals (10.76% and 11.40%, 
respectively); however, a Chinese population had 
a lower frequency.27–29 The insertion and deletion 
alleles were significantly related to hypertension in the 
current study, which correlates with the findings of a 
similar North Indian study.15
A positive correlation has been reported between 
various obesity variables like BMI and WHR, including 
oxidative stress markers such as reduced erythrocyte 
glutathione.30 In the current study, significant variation 
was found between the GSTT1-null genotype 
frequency among the hypertensive overweight/
obese and control groups. Similarly, the frequency 
of the GSTM1-positive genotype was significantly 
higher in the hypertensive overweight/obese subjects. 
However, this difference was not significant when 
compared with the hypertensive normal weight 
group. The frequencies of the GSTM1- and GSTT1-
null genotypes among hypertensive overweight/obese 
subjects in the present study (33.33% and 13.33%, 
respectively) were lower than those of non-Hispanics 
(45.30% and 81.60%, respectively), African Americans 
(72.20% and 76.20%, respectively) and Hispanics 
(46.70% and 81.70%, respectively) with higher BMIs.31 
In contrast, the frequencies of GSTM1- and GSTT1-
positive genotypes were higher when compared to 
overweight/obese non-Hispanics (54.70% and 18.40%, 
respectively), African Americans (27.80% and 23.80%, 
respectively) and Hispanics (53.30% and 18.30%, 
respectively).31 
The GSTM1- and GSTT1-positive genotype 
frequencies were somewhat higher among the 
overweight/obese hypertensives in the current study 
than for hypertensives of a normal weight, while the 
null genotype frequencies were lower among the 
former than the latter. However, these differences were 
not significant. The GSTM1- and GSTT1-positive 
genotype findings were similar across all three groups; 
nevertheless, there was a slightly higher although non-
significant frequency in the hypertensive overweight/
obese group than the hypertensive normal weight 
group. No association was found between GST 
polymorphisms and BMI in Indian diabetic patients 
with null and positive GST genotypes.11,32 Similarly, 
in Korean schizophrenic patients, no association was 
observed between GST polymorphisms and drug-
induced weight gain.12 In view of these results, it can be 
concluded that GST polymorphisms are not associated 
with a higher BMI among hypertensive patients. 
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In the present study, a significant difference 
was found between the GSTT1-null and -positive 
genotypes among hypertensives in comparison to 
control subjects. However, frequencies of GSTM1-
null and-positive genotypes were not significant. 
The frequencies of the GSTT1- and GSTM1-null 
genotypes among hypertensive patients in the current 
study (14.69% and 34.78%, respectively) were lower 
in comparison to findings from Arab (30.00% and 
60.00%, respectively), Chinese (58.10% and 60.00%, 
respectively) and Korean (55.40% and 51.80%, 
respectively, and 61.20% and 62.40%, respectively) 
populations, but similar to findings from another North 
Indian study (11.59% and 34.05%, respectively).15,33–36 
In comparison, the GSTM1-positive genotype was 
found in 65.22% of the hypertensives in the current 
study; this was higher than the results from Arab 
(40.00%), Chinese (40.00%) and Korean (48.20% and 
37.60%) populations, but again similar to results from 
a North Indian study.15,33–36
Conclusion
Among the studied North Indian population, ACE 
and GST genetic polymorphisms (particularly ACE 
insertion/insertion and GSTT1-null and -positive 
genotypes) were significantly associated with 
hypertension but not BMI. Although they were not 
significantly associated with a higher BMI, ACE and 
GST polymorphisms may nevertheless be related to 
the development of hypertension in overweight or 
obese individuals. 
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